Poolbeg Pharma identifies new potential drug candidates for RSV infections

Poolbeg Pharma is a cutting-edge biotech company with high-value therapeutic programmes and AI-led drug discovery, appealing to forward-thinking investors.

Discover how digital innovation in the pharmaceutical sector is revolutionizing drug development, accelerating treatments, and transforming healthcare.

Poolbeg Pharma secures key patent extension for POLB 001 in South Korea until December 2038, reinforcing its global IP strategy and commercial value.

Discover how Poolbeg Pharma is revolutionizing the delivery of GLP-1R agonists to combat metabolic diseases like diabetes and obesity on a global scale.

Poolbeg Pharma is gearing up for BioTrinity 2025. Don’t miss this premier life sciences event!

Discover how artificial intelligence is revolutionizing the drug development process, reducing costs, accelerating timelines, and improving patient recruitment.

Discover how AI is revolutionising drug development and protein engineering in life sciences, shaping the future of healthcare and biotechnology.

Experience the transformative era in cancer treatment strategies! Learn about groundbreaking therapies, innovative drug designs, and major advancements in oncology by 2025.

HOOKIPA Pharma is advancing HIV treatment with its Phase 1b trial for HB-500. This innovative therapy aims to boost immune responses in individuals with HIV.

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

HOOKIPA Pharma Inc. and Poolbeg Pharma plc are in discussions for a potential acquisition to create a leading biopharmaceutical company focused on innovative medicines.

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Poolbeg Pharma, led by Cathal Friel, is on the brink of a transformative merger with Hookipa Pharma, backed by Gilead Sciences. Exciting times ahead!

Gilead Sciences shows strong support for potential merger between Poolbeg Pharma and Hookipa, signaling a transformative shift in biopharma landscape.

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for

Poolbeg Pharma, led by Cathal Friel, explores merger with Hookipa for Nasdaq listing. A potential game-changer in biopharmaceutical sector.

Poolbeg Pharma’s new treatment, POLB 001, shows promise in reducing cytokine release syndrome, a common side effect of cancer immunotherapies. Learn more here.

Poolbeg Pharma presents promising data for POLB 001 at ASH Annual Meeting, showing potential in cancer immunotherapy-induced CRS. Learn more here.